First eslicarbazepine epilepsy generic to be approved in China

Genéricos/Novedades | Posted 10/12/2021 post-comment0 Post your comment

In China, the Yangtze River Pharmaceutical Group submitted the first marketing application of a class 3 generic drug, eslicarbazepine acetate, for use to treat patients with epilepsy, on 15 October 2021.

Epileptic V16F10

The eslicarbazepine acetate originator was first approved in Europe under the name of Zebinix in 2009. It is an epilepsy treatment option that acts to inhibit the repeatedly abnormal discharge of brain neurons and control epilepsy seizures by cutting the conduction of action potential. The originator drug has been shown to be well tolerated after long-term administration and has high efficacy and safety. The originator has not received marketing approval in China but in March 2021 it was included in the market of Second Batch of Suggested Generic Drugs published on the Chinese National Health Commission’s website.

The Yangtze River Pharmaceutical Group’s eslicarbazepine acetate is likely to be the first generic drug approved. However, Sihuan Pharm, Changzhou Pharmaceutical Factory, HUAWE and a number of other pharmaceutical developers are also in the process of creating or having generic versions of eslicarbazepine acetate approved in China.

Eslicarbazepine acetate will not be the first generic epilepsy drug on the market in China. It will join three other antiepileptic drugs, vigabatrin, brivaracetam and fycompa, that are currently on the market in China.

Related articles
New Alvotech partnerships in South Africa and China

Teva receives FDA approval for Sabril and launches Elidel cream

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: La evidencia sobre la sustitución automática de biológicos es limitada

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: La evidencia sobre la sustitución automática de biológicos es limitada

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Pfizer and Merck COVID-19 antiviral progress
26 AA011066
Genéricos/Novedades Posted 12/11/2021
Sun Pharma and Dr Reddy’s generics progress in EU and US
Diabetes V14K06
Genéricos/Novedades Posted 05/11/2021
Oncology generics launched by MSN Labs and Natco Pharma
84 MD002440
Genéricos/Novedades Posted 29/10/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010